Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HistoSeps phase I study of intravenous M6229 in critically ill sepsis patients
NL-OMON51932Phase 1Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of isupartob sodium in sepsis, sponsored by Amsterdam University Medical Center. Primary endpoints: Change in activated partial thromboplastin time, Plasma pharmacokinetic parameters of M6229 and 1 more. Started Apr 2022; status: active, not recruiting.
02
Drugs
isupartob sodium
03
Conditions
sepsis
Beyond the preview
Go deeper on NL-OMON51932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51932.